Sign in with Google
CCDS
Join our community on Telegram!
Join the biggest community of Pharma students and professionals.
What Is CCDS?
CCDS stands for Company Core Data Sheet. It is a global regulatory document prepared by the Marketing Authorization Holder that defines the company’s official position on the safety, efficacy, and prescribing information of a medicinal product across all countries where it is marketed.
Unlike USPI or SmPC, which are approved by regulatory authorities, the CCDS is an internal company document. It serves as the master reference document for developing and updating country-specific labels worldwide. It ensures global consistency in safety information and risk communication.
Regulatory Context
The CCDS is not directly approved by any single regulatory authority, but it is aligned with international pharmacovigilance standards defined by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It plays a central role in global safety reporting and labeling harmonization.
Regulatory Positioning
| Parameter | CCDS |
|---|---|
| Document Type | Company-controlled global labeling document |
| Approval Status | Not directly approved by authorities |
| Owner | Marketing Authorization Holder |
| Purpose | Global harmonization of product information |
| Regulatory Link | Supports PSUR/PBRER and labeling updates |
Purpose of CCDS
The CCDS establishes the company’s core safety information and core prescribing information for a product. It acts as the foundation for preparing country-specific labeling documents such as USPI in the United States and SmPC in the European Union. It also supports pharmacovigilance activities by defining Core Safety Information.
Structure of CCDS
The CCDS typically contains two major components.
| Component | Description |
|---|---|
| Company Core Safety Information (CCSI) | Essential safety information considered important by the company |
| Core Prescribing Information | Global prescribing framework including indications and dosage |
Company Core Safety Information is a critical part of the CCDS. It includes safety information that the company believes should be included in labeling worldwide. Regulatory authorities often compare local labels against the CCSI during inspections to ensure timely implementation of safety updates.
Typical Content Structure
Although there is no legally fixed format like USPI or SmPC, most CCDS documents follow a structure similar to professional labeling.
| Major Section | Content |
|---|---|
| Indications | Approved global therapeutic uses |
| Dosage and Administration | Core dosing principles |
| Contraindications | Absolute restrictions |
| Warnings and Precautions | Important risk information |
| Adverse Reactions | Core safety profile |
| Drug Interactions | Known interaction risks |
| Use in Special Populations | Pregnancy, pediatric, geriatric use |
| Overdose | Management guidance |
| Pharmacology | Mechanism and pharmacokinetics |
CCDS vs Country-Specific Labeling
| Parameter | CCDS | USPI | SmPC |
|---|---|---|---|
| Scope | Global company standard | United States | European Union |
| Approval | Internal company approval | FDA approved | EMA/National Authority approved |
| Legal Status | Not legally binding externally | Legally binding | Legally binding |
| Update Trigger | Global safety review | FDA supplement | EU variation |
Role in Pharmacovigilance
The CCDS is directly linked to periodic safety reporting. During preparation of Periodic Safety Update Reports or Periodic Benefit-Risk Evaluation Reports, safety data is evaluated globally. If new risks are identified, the CCDS is updated first. After internal approval, country affiliates implement corresponding changes into local labels through regulatory submissions.
This process ensures synchronized global risk communication and prevents discrepancies between countries.
Lifecycle Management
The CCDS is a living document. Updates may occur due to new clinical trial data, post-marketing safety signals, regulatory authority requests, literature findings, or risk management plan modifications. Once revised, global affiliates are notified to assess the need for local label variations.
Importance in Regulatory Affairs and Medical Writing
For regulatory professionals, understanding CCDS is essential for global labeling strategy and compliance. Medical writers draft and revise CCDS documents based on integrated safety analyses and global clinical data. Strong coordination between global safety, regulatory affairs, and local affiliates is required to maintain alignment.
In inspections, authorities may review whether local labeling aligns with the Company Core Safety Information and whether safety changes were implemented in a timely manner.
